Cogent Soars on Positive Mid-Stage Data in Rare Blood Disorder

In a presentation at the 2022 European Hematology Association Congress in Austria, Cogent Biosciences shared results from its Phase II APEX clinical trial on bezuclastinib, which is being developed to treat patients with advanced systemic mastocytosis (AdvSM). The drug showed promise in treating the rare blood disorder.